Caliway Biopharmaceuticals

Update in progress

6919.TW (Taiwan)

Caliway Biopharmaceuticals Co., Ltd. and its subsidiaries develop drugs for aesthetic medicine and chronic inflammation. The company is advancing CBL-514, in Phase 2 for non-surgical fat reduction, Dercum’s disease, and cellulite treatment. It is also pursuing CBA-539, in preclinical stages for central obesity, hyperpigmentation, and skin aging, and offers dietary supplements. Founded in 2012, based in New Taipei City, Taiwan.